Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 20398713)

1.

A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease.

Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, McGowan E, Emson PC, Griffin JL.

Neurochem Int. 2010 Jul;56(8):937-47. doi: 10.1016/j.neuint.2010.04.001. Epub 2010 Apr 14.

PMID:
20398713
2.

1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages.

Lalande J, Halley H, Balayssac S, Gilard V, Déjean S, Martino R, Francés B, Lassalle JM, Malet-Martino M.

J Alzheimers Dis. 2014;39(1):121-43. doi: 10.3233/JAD-130023.

PMID:
24145382
3.

Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease.

González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL.

Biochim Biophys Acta. 2014 Dec;1842(12 Pt A):2395-402. doi: 10.1016/j.bbadis.2014.09.014. Epub 2014 Oct 2.

PMID:
25281826
4.

Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein.

Bates KA, Fonte J, Robertson TA, Martins RN, Harvey AR.

Neuroscience. 2002;113(4):785-96.

PMID:
12182886
5.

Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw).

Nordberg A, Hellström-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J.

J Neurochem. 2002 May;81(3):655-8.

PMID:
12065674
6.

A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.

Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC.

J Alzheimers Dis. 2010;20(1):113-26. doi: 10.3233/JAD-2010-1349.

PMID:
20164597
7.

Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease.

Hashimoto T, Ogino K, Shin RW, Kitamoto T, Kikuchi T, Shimizu N.

Neurosci Lett. 2010 Jan 22;469(2):273-7. doi: 10.1016/j.neulet.2009.12.015. Epub 2009 Dec 16.

PMID:
20025930
8.

Histochemical visualization and diffusion MRI at 7 Tesla in the TgCRND8 transgenic model of Alzheimer's disease.

Thiessen JD, Glazner KA, Nafez S, Schellenberg AE, Buist R, Martin M, Albensi BC.

Brain Struct Funct. 2010 Jul;215(1):29-36. doi: 10.1007/s00429-010-0271-z. Epub 2010 May 29.

PMID:
20512361
9.

Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.

Van Dam D, Marescau B, Engelborghs S, Cremers T, Mulder J, Staufenbiel M, De Deyn PP.

Neurochem Int. 2005 Apr;46(5):409-22. Epub 2005 Jan 17.

PMID:
15737439
10.

Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain.

Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF.

Neuroscience. 2000;101(4):939-44.

PMID:
11113343
11.

PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB.

Eur J Nucl Med Mol Imaging. 2005 May;32(5):593-600. Epub 2005 Mar 25.

PMID:
15791432
12.

Possible involvement of transthyretin in hippocampal beta-amyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8).

Doggui S, Brouillette J, Chabot JG, Farso M, Quirion R.

Neurodegener Dis. 2010;7(1-3):88-95. doi: 10.1159/000285513. Epub 2010 Feb 18.

PMID:
20173334
13.

Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease.

Adlard PA, Perreau VM, Pop V, Cotman CW.

J Neurosci. 2005 Apr 27;25(17):4217-21.

14.

Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS.

Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, Rhim HS, Choi CB, Kim HY, Lee CU, Choe BY.

Behav Brain Res. 2010 Jul 29;211(1):125-31. doi: 10.1016/j.bbr.2010.03.026. Epub 2010 Mar 20.

PMID:
20307581
15.

Inflammation occurs early during the Abeta deposition process in TgCRND8 mice.

Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, Gervais F.

Neurobiol Aging. 2004 Aug;25(7):861-71.

PMID:
15212840
16.

Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice.

Hanna A, Horne P, Yager D, Eckman C, Eckman E, Janus C.

Genes Brain Behav. 2009 Oct;8(7):676-84. doi: 10.1111/j.1601-183X.2009.00510.x. Epub 2009 May 26.

PMID:
19531156
17.

Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease.

Richardson JC, Kendal CE, Anderson R, Priest F, Gower E, Soden P, Gray R, Topps S, Howlett DR, Lavender D, Clarke NJ, Barnes JC, Haworth R, Stewart MG, Rupniak HT.

Neuroscience. 2003;122(1):213-28.

PMID:
14596862
18.

Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease.

Giovannini MG, Cerbai F, Bellucci A, Melani C, Grossi C, Bartolozzi C, Nosi D, Casamenti F.

Neuroscience. 2008 May 15;153(3):618-33. doi: 10.1016/j.neuroscience.2008.02.061. Epub 2008 Mar 6.

PMID:
18406062
19.

Cholinergic neuropathology in a mouse model of Alzheimer's disease.

German DC, Yazdani U, Speciale SG, Pasbakhsh P, Games D, Liang CL.

J Comp Neurol. 2003 Aug 4;462(4):371-81.

PMID:
12811807
20.

Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease.

Vaisid T, Kosower NS, Katzav A, Chapman J, Barnoy S.

Neurochem Int. 2007 Nov-Dec;51(6-7):391-7. Epub 2007 Apr 19.

PMID:
17513017
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk